Article Text

PDF
MR spectroscopy indicates diffuse multiple sclerosis activity during remission
  1. I I Kirov1,
  2. V Patil1,
  3. J S Babb1,
  4. H Rusinek1,
  5. J Herbert2,
  6. O Gonen1
  1. 1
    Department of Radiology, New York University School of Medicine, New York, USA
  2. 2
    Department of Neurology, New York University School of Medicine, New York, USA
  1. Correspondence to Professor O Gonen, Department of Radiology, New York University School of Medicine, 660 First Avenue, 4th Floor, New York, NY 10016, USA; oded.gonen{at}nyumc.org

Abstract

Objective: To test the hypothesis that diffuse abnormalities precede axonal damage and atrophy in the MRI normal-appearing tissue of relapsing-remitting (RR) multiple sclerosis (MS) patients, and that these processes continue during clinical remission.

Methods: Twenty-one recently diagnosed mildly disabled (mean disease duration 2.3 years, mean Expanded Disability Status Scale score of 1.4) RR MS patients and 15 healthy matched controls were scanned with MRI and proton MR spectroscopic imaging (1H-MRSI) at 3 T. Metabolite concentrations: N-acetylaspartate (NAA) for neuronal integrity; choline (Cho) for membrane turnover rate; creatine (Cr) and myo-inositol (mI) for glial status were obtained in a 360 cm3 volume of interest (VOI) with 3D multivoxel 1H-MRSI. They were converted into absolute amounts using phantom replacement and normalised into absolute concentrations by dividing by the VOI tissue volume fraction obtained from MRI segmentation.

Results: The patients’ mean VOI tissue volume fraction, 0.92 and NAA concentration, 9.6 mM, were not different from controls’ 0.94 and 9.6 mM. In contrast, the patients’ mean Cr, Cho and mI levels 7.7, 1.9 and 4.1 mM were 9%, 14% and 20%, higher than the controls’ 7.1, 1.6 and 3.4 mM (p = 0.0097, 0.003 and 0.0023).

Conclusions: The absence of early tissue atrophy and apparent axonal dysfunction (NAA loss) in these RR MS patients suggests that both are preceded by diffuse glial proliferation (astrogliosis), as well as possible inflammation, demyelination and remyelination reflected by elevated mI, Cho and Cr, even during clinical remission and despite immunomodulatory treatment.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This work was supported by NIH Grants NS050520, NS29029 and EB01015.

  • Competing interests None.

  • Ethics approval Ethics approval was provided by New York University School of Medicine Institutional Review Board.

  • Patient consent Obtained.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.